Jove
Visualize
Contact Us

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cannabidiol and pBDNF Cotreatment Attenuates Pathological Symptoms and Improves Cognition in 3 month-Old 5XFAD Mice.

ACS chemical neuroscience·2026
Same author

Mesenchymal Stem Cell Exosome-Mediated Delivery of Paclitaxel for Pancreatic Cancer Therapy.

Biomolecules·2026
Same author

Engineered PLGA Nanoparticles for Brain-Targeted Codelivery of Cannabidiol and pApoE2 through the Intranasal Route for the Treatment of Alzheimer's Disease.

ACS biomaterials science & engineering·2025
Same author

Synthesis and Characterization of Transferrin and Cell-Penetrating Peptide-Functionalized Liposomal Nanoparticles to Deliver Plasmid ApoE2 <i>In Vitro</i> and <i>In Vivo</i> in Mice.

Molecular pharmaceutics·2024
Same author

Penetratin and Mannose-Functionalized Cannabidiol Lipid Nanoparticles Encapsulating the BDNF Gene Reduce Amyloid-Induced Inflammation.

Molecular pharmaceutics·2024
Same author

Mannose-Functionalized Chitosan-Coated PLGA Nanoparticles for Brain-Targeted Codelivery of CBD and BDNF for the Treatment of Alzheimer's Disease.

ACS chemical neuroscience·2024
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 28, 2026

A Thin-skull Window Technique for Chronic Two-photon In vivo Imaging of Murine Microglia in Models of Neuroinflammation
12:07

A Thin-skull Window Technique for Chronic Two-photon In vivo Imaging of Murine Microglia in Models of Neuroinflammation

Published on: September 19, 2010

Recent Nanotherapeutic Advancements Against HIV-Associated Neurocognitive Disorders (HAND).

Riddhi Trivedi1, Avinash Gothwal1, Buddhadev Layek1

  • 1Department of Pharmaceutical Sciences, North Dakota State University, Fargo, ND 58102, USA.

Biomolecules
|May 27, 2026
PubMed
Summary

HIV-associated neurocognitive disorders (HAND) persist despite treatment due to limited drug delivery to the brain. Nanoliterapeutic strategies show promise for enhancing antiretroviral drug penetration across the blood-brain barrier to combat HAND.

Keywords:
HANDantiretroviral therapyblood–brain barrier

More Related Videos

Identification of EcoHIV-Infected Cells in Microglia-Manipulated Transgenic Mice
07:23

Identification of EcoHIV-Infected Cells in Microglia-Manipulated Transgenic Mice

Published on: December 20, 2024

A Rat Model of EcoHIV Brain Infection
08:48

A Rat Model of EcoHIV Brain Infection

Published on: January 21, 2021

Related Experiment Videos

Last Updated: May 28, 2026

A Thin-skull Window Technique for Chronic Two-photon In vivo Imaging of Murine Microglia in Models of Neuroinflammation
12:07

A Thin-skull Window Technique for Chronic Two-photon In vivo Imaging of Murine Microglia in Models of Neuroinflammation

Published on: September 19, 2010

Identification of EcoHIV-Infected Cells in Microglia-Manipulated Transgenic Mice
07:23

Identification of EcoHIV-Infected Cells in Microglia-Manipulated Transgenic Mice

Published on: December 20, 2024

A Rat Model of EcoHIV Brain Infection
08:48

A Rat Model of EcoHIV Brain Infection

Published on: January 21, 2021

Area of Science:

  • Neuroscience
  • Pharmacology
  • Nanotechnology

Background:

  • HIV infection of the central nervous system causes HAND, leading to cognitive, motor, and behavioral impairments.
  • HAND remains prevalent despite combination antiretroviral therapy (cART) due to poor drug penetration across the blood-brain barrier (BBB).
  • Limited BBB penetration allows persistent viral reservoirs and ongoing neuroinflammation, driving neuronal damage.

Purpose of the Study:

  • To review the pathophysiological challenges of HAND.
  • To discuss recent advances in nanotherapeutic strategies for improved antiretroviral drug delivery to the brain.
  • To evaluate current in vitro and in vivo models for testing nanotherapeutics against HAND.

Main Methods:

  • Review of existing literature on HAND pathophysiology and nanotherapeutic approaches.
  • Analysis of nanotherapeutic strategies for enhanced drug delivery across the BBB.
  • Discussion of in vitro and in vivo models for evaluating nanotherapeutic efficacy.

Main Results:

  • Nanotherapeutic strategies, including targeted delivery and co-delivery systems, are being developed to overcome BBB limitations.
  • These nanotherapeutics aim to improve antiretroviral agent concentration in the CNS.
  • Various in vitro and in vivo models are employed to assess the efficacy of these advanced treatments.

Conclusions:

  • Nanotherapeutics offer a promising avenue for improving HAND treatment by enhancing drug delivery to the brain.
  • Further research and development are needed to overcome remaining challenges in nanotherapeutic application for HAND.
  • Future prospects involve refining nanotherapeutic designs and validating their clinical efficacy for HAND management.